The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in healthy matched control participants with normal hepatic function.
Hepatic Impairment, Healthy Volunteers
The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in healthy matched control participants with normal hepatic function.
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
-
Local Institution - 0006, Miami Lakes, Florida, United States, 33014-2811
Panax Clinical Research, Miami Lakes, Florida, United States, 33014
Local Institution - 0005, Orlando, Florida, United States, 32809-3017
Orlando Clinical Research Center, Orlando, Florida, United States, 32809
Local Institution - 0004, San Antonio, Texas, United States, 78215
Texas Liver Institute, San Antonio, Texas, United States, 78215
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 75 Years
ALL
Yes
Bristol-Myers Squibb,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2025-07-24